SavedAdd your journal

Journals / Türk Nöroloji Dergisi / 2009 / Cilt: 15 - Sayı: 4

Migren hastalarında anjiyotensin dönüştürücü enzim gen insersiyon/delesyon polimorfizmi

Angiotensin converting enzyme gene insertion/deletion polymorphism in migraine patients

Aylin AKÇALI
Münife NEYAL
Belgin ALAŞEHİRLİ
Sırma GEYİK
Abdurrahman NEYAL
Mehmet GÜR
Binnur BÜLBÜL
Derya SAYAR
Mustafa YILMAZ
Pages
161–165
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: We believe that further angiotensin converting enzyme gene studies are warranted in younger age groups of patients with migraine and also in different populations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: The beneficial effects of angiotensin converting enzyme inhibitor drugs on migraine attack frequency have been shown.
📊
Key Findings & Data:METHODS: In the present study, to assess whether the angiotensin converting enzyme insertion/deletion (I/D) gene polymorphisms have an effect on migraine attacks, we studied the angiotensin converting enzyme genotypes of 102 migraine patients (35 cases of migraine with aura and 67 of migraine without aura) and 75 age-and sex-matched normal volunteers.
💡
Conclusion & Impact:CONCLUSION: We believe that further angiotensin converting enzyme gene studies are warranted in younger age groups of patients with migraine and also in different populations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: The beneficial effects of angiotensin converting enzyme inhibitor drugs on migraine attack frequency have been shown. We aimed to study the relationship between the angiotensin converting enzyme gene and migraine pathophysiology. METHODS: In the present study, to assess whether the angiotensin converting enzyme insertion/deletion (I/D) gene polymorphisms have an effect on migraine attacks, we studied the angiotensin converting enzyme genotypes of 102 migraine patients (35 cases of migraine with aura and 67 of migraine without aura) and 75 age-and sex-matched normal volunteers. Frequency and age of onset of migraine attacks were also assessed according to angiotensin converting enzyme genotypes. RESULTS: Patients with migraine with and without aura were comparable with each other and the control group with respect to angiotensin converting enzyme genotypes (respectively; p= 0.88 and p= 0.76, p= 0.624). We could not determine a relationship between angiotensin converting enzyme genotypes and attack frequency (p= 0.125), but cases with angiotensin converting enzyme-II genotype showed a significantly younger age for onset of migraine attacks in comparison with the I/D genotype patients (p= 0.021). CONCLUSION: We believe that further angiotensin converting enzyme gene studies are warranted in younger age groups of patients with migraine and also in different populations.

Özet

AMAÇ: Anjiyotensin dönüştürücü enzim inhibitörü ilaçların migren atak sıklığı üzerine etkili oldukları gösterilmiştir. Bu çalışmada anjiyotensin dönüştürücü enzim geninin migren patofizyolojisi ile ilişkisi araştırılmak istenmiştir. YÖNTEMLER: Anjiyotensin dönüştürücü enzim geninin I/D polimorfizmlerinin migren atakları ile ilişkisini araştırmak üzere 102 migren hastası (35 auralı migren, 67 aurasız migren) ile yaş ve cinsiyet olarak uygun 75 kontrol üzerinde çalışılmıştır. Migren atak sıklığı ve başlangıç yaşları da anjiyotensin dönüştürücü enzim genotipleri ile beraber değerlendirilmiştir. BULGULAR: Auralı ve aurasız migren hastaları ve kontrol grubu anjiyotensin dönüştürücü enzim genotipleri yönünden birbirileri ile karşılaştırılabilir olarak gözlendi (sırasıyla; p= 0.88 ve p= 0.76, p= 0.624). Atak sıklığı ile anjiyotensin dönüştürücü enzim genotipleri arasında ilişki saptanmadı (p= 0.125) ancak anjiyotensin dönüştürücü enzim-II genotipine sahip olanlarda migren atakları daha genç yaşta başlıyordu (p= 0.021). SONUÇ: Anjiyotensin dönüştürücü enzim gen polimorfizmi ile ilgili farklı popülasyonlarda ve genç migren hastalarında çalışmalara ihtiyaç vardır.

🔖

Cite This Article

AKÇALI, A., NEYAL, M., ALAŞEHİRLİ, B., GEYİK, S., NEYAL, A., GÜR, M., BÜLBÜL, B., SAYAR, D., YILMAZ, M. (2022). Migren hastalarında anjiyotensin dönüştürücü enzim gen insersiyon/delesyon polimorfizmi. Türk Nöroloji Dergisi, Cilt: 15 - Sayı: 4, 161–165. https://ajindex.com/articles/637010

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Crisan D, Carr J. Angiotensin I-converting enzyme, genetic and disease association review. J Mol Diagnostic 2000;3:105-12
  2. Cambien FF, Alhenc-Gelas B, Herbeth JL, Andre R, Rakotovao MF, Gonzales J, et al. Familial resemblance of plasma angiotensin-converting enzyme level: The Nancy study. Am J Hum Genet 1988;43:774-80
  3. Evans AE, Poirier O, Kee F, Lecerf L, McCrum E, Falconer T, et al. Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. Q J Med 1994;87:211-4
  4. Mattace-Raso FU, van der Cammen TJ, Sayed-Tabatabaei FA, Van Popele NM, Asmar R, Schalekamp MA, et al. Angiotensin converting enzyme gene polymorphism and common carotid stiffness. The Rotterdam study. Atherosclerosis 2004;174:121-6
  5. Mattu RK, Needham EW, Galton DJ, Frangos E, Clark AJ, Caulfield M. A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart study. Circulation 1995;15:270-4
  6. Nakai K, Fusazaki T, Zhang T, Shiroto T, Osawa M, Kamata J, et al. Polymorphism of the apolipoprotein E and angiotensin I converting enzyme genes in Japanese patients with myocardial infarction. Coron Artery Dis 1998;9:329-34
  7. Zhang JH, Kohara K, Yamamoto Y, Nakura J, Tabaro Y, Fujisawa M, et al. Genetic predisposition to neurological symptoms in lacunar infarction. Cerebrovasc Dis 2004;17:273-9
  8. Paterna S, Di Pasquale P, D’Angelo A, Seidita G, Tuttolomondo A, Cardinale A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 2000;43:133-6
  9. Joshi G, Pradhan S, Mittal B. Role of the ACE ID and MTHFR C677T polymorphisms in genetic susceptibility of migraine in a north Indian population. J Neurol Sci 2009;277:133-7
  10. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC. et al. Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy-a pilot study. Pharmacoepidemiol Drug Saf 2004;13:41-7
  11. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomised, placebo controlled, crossover study. BMJ 2001;322:19
  12. Schuh-Hofer S, Flach U, Meisel A, Israel H, Reuter U, Arnold G. Efficacy of lisinopril in migraine prophylaxis-an open label study. Eur J Neurol 2007;14:701-3
  13. Headache Classification Committee of